[Importance of local skin treatments during radiotherapy for prevention and treatment of radio-induced epithelitis].
Radio-epithelitis represents a common problem, for which treatments are characterized by a great heterogeneity. The present review of literature focuses on data referenced in Pubmed((c))/Medline((c)) and published in French/English. Despite a real preclinical rationale, aloe vera and trolamine failed to demonstrate any benefit in the prophylactic settings. In a prospective assessment phase III assessment, Calendula Officinalis was shown to be superior to trolamine for the prevention of radio-epithelitis. In the curative settings, sucrafalte failed to demonstrate any benefit. The benefit of dermocorticoids was suggested in terms of erythema and itching. Promising clinical results are available with hyaluronic acid (MA S065D and Ialugen) and silver leaf may reduce the intensity of cutaneous radio-induced side effects. Data from the literature are conflicting, making real the difficulty to adopt from clinical trials any proof-of-principle strategy. Considering these uncertainties, several strategies are allowed. New topics are under investigation. Present data from the literature highlight the need for further trials, in order to propose evidence-based treatments and to harmonize clinical practice.
Chargari
C
C
Département de radiothérapie oncologique, Institut Curie, 26 rue d'Ulm, Paris, France.
Fromantin
I
I
Kirova
Y M
YM
D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000504:Aloe; D020838:Calendula; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004655:Emulsions; D004801:Eosine Yellowish-(YS) / Q000008:administration & dosage; D005227:Fatty Acids / Q000008:administration & dosage; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage; D008055:Lipids / Q000008:administration & dosage; D008517:Phytotherapy; D028321:Plant Preparations / Q000008:administration & dosage*; D011855:Radiodermatitis / Q000517:prevention & control* / Q000628:therapy; D011878:Radiotherapy / Q000009:adverse effects*; D012459:Salicylates / Q000008:administration & dosage; D012717:Sesquiterpenes / Q000008:administration & dosage; D013392:Sucralfate / Q000008:administration & dosage
D000305:Adrenal Cortex Hormones; C423724:Biafine; D003879:Dermatologic Agents; D004655:Emulsions; D005227:Fatty Acids; C423725:Lipiderm; D008055:Lipids; D028321:Plant Preparations; D012459:Salicylates; D012717:Sesquiterpenes; D013392:Sucralfate; D006820:Hyaluronic Acid; C032758:trolamine salicylate; D004801:Eosine Yellowish-(YS)